Sorafenib and radiotherapy association for hepatocellular carcinoma;Sorafénib et radiothérapie dans le carcinome hépatocellulaire

Cancer/Radiotherapie

Volumn 15, Issue 1, 2011, Pages 77-80

  Girard, N ^a,b   Mornex, F ^b,c  

^a LOUIS PRADEL HOSPITAL   (France)

^b UNIVERSITÉ LYON 1   (France)

^c CENTRE HOSPITALIER LYON SUD   (France)

Author keywords

BRAF; ERK; Hepatocellular carcinoma; Radiotherapy; Sorafenib; Treatment; VEGF

Indexed keywords

B RAF KINASE; MITOGEN ACTIVATED PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; SORAFENIB; VASCULOTROPIN RECEPTOR;

DRUG EFFECT; DRUG EFFICACY; HUMAN; LIVER CELL CARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN TARGETING; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; HUMANS; LIVER NEOPLASMS; PROTO-ONCOGENE PROTEINS B-RAF; PYRIDINES; RADIOTHERAPY, ADJUVANT; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79551506128     PISSN: 12783218     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canrad.2010.11.012     Document Type: Short Survey

References (27)

1. Parkin D.M. Global cancer statistics in the year 2000. Lancet Oncol 2001, 2:533-543.
2. Llovet J.M., Burroughs A., Bruix J. Hepatocellular carcinoma. Lancet 2003, 362:1907-1917.
3. Mornex F., Girard N., Beziat C., Kubas A., Khodri M., Trepo C., et al. Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies - mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 2006, 66:1152-1158.
4. Girard N., Mornex F. Radiothérapie externe des carcinomes hépato-cellulaires. Cancer Radiother 2011, 15:49-53.
5. Liang S.X., Zhu X.D., Lu H.J., Pan C.Y., Li F.X., Huang Q.F., et al. Hypofractionated three-dimensional conformal radiation therapy for primary liver carcinoma. Cancer 2005, 103:2181-2188.
6. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. doi:10.1016/S1470-2045(10)70087-5.
7. Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
8. Cheng A.L., Kang Y.K., Chen Z., Tsao C.J., Qin S., Kim J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
9. Gupta A.K., Bakanauskas V.J., Cerniglia G.J., Cheng Y., Bernhard E.J., Muschel R.J., et al. The Ras radiation resistance pathway. Cancer Res 2001, 61:4278-4282.
10. Samuni A.M., Kasid U., Chuang E.Y., Suy S., Degraff W., Krishna M.C., et al. Effects of hypoxia on radiation-responsive stress-activated protein kinase, p53, and caspase 3 signals in TK6 human lymphoblastoid cells. Cancer Res 2005, 65:579-586.
11. Jalal Hosseinimehr S., Inanami O., Hamasu T., Takahashi M., Kashiwakura I., Asanuma T., et al. Activation of c-kit by stem cell factor induces radioresistance to apoptosis through ERK-dependent expression of survivin in HL60 cells. J Radiat Res 2004, 45:557-561.
12. Cheng J.C., Chou C.H., Kuo M.L., Hsieh C.Y. Radiation-enhanced hepatocellular carcinoma cell invasion with MMP-9 expression through PI3K/Akt/NF-kappaB signal transduction pathway. Oncogene 2006, 25:7009-7018.
13. Moon W.S., Rhyu K.H., Kang M.J., Lee D.G., Yu H.C., Yeum J.H., et al. Overexpression of VEGF and angiopoietin 2: a key to high vascularity of hepatocellular carcinoma?. Mod Pathol 2003, 16:552-557.
14. Yoshiji H., Kuriyama S., Yoshii J., Yamazaki M., Kikukawa M., Tsujinoue H., et al. Vascular endothelial growth factor tightly regulates in vivo development of murine hepatocellular carcinoma cells. Hepatology 1998, 28:1489-1496.
15. Chung Y.L., Jian J.J., Cheng S.H., Tsai S.Y., Chuang V.P., Soong T., et al. Sublethal irradiation induces vascular endothelial growth factor and promotes growth of hepatoma cells: implications for radiotherapy of hepatocellular carcinoma. Clin Cancer Res 2006, 12:2706-2715.
16. Williams K.J., Telfer B.A., Xenaki D., Sheridan M.R., Desbaillets I., Peters H.J., et al. Enhanced response to radiotherapy in tumours deficient in the function of hypoxia-inducible factor-1. Radiother Oncol 2005, 75:89-98.
17. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004, 14:198-206.
18. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995, 1:27-31.
19. Jain R.K. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
20. Plastaras J.P., Kim S.H., Liu Y.Y., Dicker D.T., Dorsey J.F., McDonough J., et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007, 67:9443-9454.
21. Chi K.H., Liao C.S., Chang C.C., Ko H.L., Tsang Y.W., Yang K.C., et al. Angiogenic blockade and radiotherapy in hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2010, 78:188-193.
22. Hsieh C.H., Jeng K.S., Lin C.C., Chen C.K., Liu C.Y., Lin C.P., et al. Combination of sorafenib and intensity modulated radiotherapy for unresectable hepatocellular carcinoma. Clin Drug Investig 2009, 29:65-71.
23. Zhao J.D., Liu J., Ren Z.G., Gu K., Zhou Z.H., Li W.T., et al. Maintenance of Sorafenib following combined therapy of three-dimensional conformal radiation therapy/intensity-modulated radiation therapy and transcatheter arterial chemoembolization in patients with locally advanced hepatocellular carcinoma: a phase I/II study. Radiat Oncol 2010, 5:12.
24. Peters N.A., Richel D.J., Verhoeff J.J., Stalpers L.J. Bowel perforation after radiotherapy in a patient receiving sorafenib. J Clin Oncol 2008, 26:2405-2406.
25. Diaz O., Mazeron R., Martin E., Carrie C. Toxicité de l'association radiothérapie et antiangiogéniques: à propos d'un cas. Cancer Radiother 2009, 13:205-208.
26. Chung C., Dawson L.A., Joshua A.M., Brade A.M. Radiation recall dermatitis triggered by multi-targeted tyrosine kinase inhibitors: sunitinib and sorafenib. Anticancer Drugs 2010, 21:206-209.
27. De Bari B., Pointreau Y., Rio E., Mirabel X., Mornex F. Dose de tolérance à l'irradiation des tissus sains: le foie. Cancer Radiother 2010, 14:344-349.